Retension Pharmaceuticals Appoints Alison Schecter as Chief Medical Officer and Alex Schwartz as Chief Financial Officer

Retension Pharmaceuticals closes $15 million Series B financing to advance RTN-001 for uncontrolled hypertension. The funding supports Phase 2b trials and a new patent issuance.

Retension Pharmaceuticals

Retension Pharmaceuticals raised $10.4 million in a Series A funding led by undisclosed investors to fund clinical trials for patients suffering from resistant and uncontrolled hypertension.

Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patien

Retension Pharmaceuticals

Funding history

Recent signals